|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Hepatitis c virus ns3 proteinase
|
|
Structure:
|
 |
Ns3 proteinase. Chain: a, b, c. Engineered: yes
|
|
Source:
|
 |
Hepatitis c virus. Organism_taxid: 11103. Strain: type 1b. Variant: bk isolate. Gene: cdna. Expressed in: escherichia coli. Expression_system_taxid: 562. Isolated from pat. Other_details: expressed as soluble protein
|
|
Resolution:
|
 |
|
2.40Å
|
R-factor:
|
0.225
|
R-free:
|
0.320
|
|
|
Authors:
|
 |
R.A.Love,H.E.Parge,J.A.Wickersham,Z.Hostomsky,N.Habuka, E.W.Moomaw,T.Adachi,Z.Hostomska
|
Key ref:
|
 |
R.A.Love
et al.
(1996).
The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.
Cell,
87,
331-342.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
12-Dec-97
|
Release date:
|
25-Mar-98
|
|
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
Chains A, B, C:
E.C.2.7.7.48
- RNA-directed Rna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1)
|
 |
 |
 |
 |
 |
Nucleoside triphosphate
|
+
|
RNA(n)
|
=
|
diphosphate
|
+
|
RNA(n+1)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chains A, B, C:
E.C.3.4.21.98
- Hepacivirin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Hydrolysis of four peptide bonds in the viral precursor polyprotein, commonly with Asp or Glu in the P6 position, Cys or Thr in P1 and Ser or Ala in P1'.
|
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
Chains A, B, C:
E.C.3.6.1.15
- Nucleoside-triphosphatase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
NTP + H2O = NDP + phosphate
|
 |
 |
 |
 |
 |
NTP
|
+
|
H(2)O
|
=
|
NDP
|
+
|
phosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
Chains A, B, C:
E.C.3.6.4.13
- Rna helicase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
ATP + H2O = ADP + phosphate
|
 |
 |
 |
 |
 |
ATP
|
+
|
H(2)O
|
=
|
ADP
|
+
|
phosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Biological process
|
transformation of host cell by virus
|
2 terms
|
 |
|
Biochemical function
|
catalytic activity
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Cell
87:331-342
(1996)
|
|
PubMed id:
|
|
|
|
|
| |
|
The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.
|
|
R.A.Love,
H.E.Parge,
J.A.Wickersham,
Z.Hostomsky,
N.Habuka,
E.W.Moomaw,
T.Adachi,
Z.Hostomska.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
During replication of hepatitis C virus (HCV), the final steps of polyprotein
processing are performed by a viral proteinase located in the N-terminal
one-third of nonstructural protein 3. The structure of NS3 proteinase from HCV
BK strain was determined by X-ray crystallography at 2.4 angstrom resolution.
NS3P folds as a trypsin-like proteinase with two beta barrels and a catalytic
triad of His-57, Asp-81, Ser-139. The structure has a substrate-binding site
consistent with the cleavage specificity of the enzyme. Novel features include a
structural zinc-binding site and a long N-terminus that interacts with
neighboring molecules by binding to a hydrophobic surface patch.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 4.
Figure 4. Model of a Bound Polypeptide Substrate Containing
the NS3/4A JunctionSide-by-side stereo view of the NS3/4A
substrate (color-coded: green, C; red, O; blue, N) modeled into
the active site of HCV NS3P, which is covered by a molecular
surface in white dots (generated by the MS program[12] using a
1.6 Šprobe radius). The Cα trace of NS3P is shown in
yellow, with the oxyanion-stabilizing loop in purple and the
extended strand βE2 in red. NS3P side chains (color-coded:
yellow, C; red, O; blue, N) are shown for residues comprising
the S1 specificity pocket (L135, F154, A157), the potential P6
recognition elements (R161, K165), and active-site serine
(S139). The substrate is labeled according to the standard P/P'
convention, while the HCV residues are labeled in the
single-letter amino acid code.
|
 |
Figure 5.
Figure 5. Solvent-Accessible Surface of NS3P Monomer 1,
Colored by Hydrophobicity, Such That Nonpolar Residues Are
White, Charged Residues Are Deep Magenta, and Polar Residues Are
Medium Shades of MagentaThe central white region is the
hydrophobic patch (approximately 400 Å^2) discussed in the
text. In the crystal, there are two N-terminal strands from
neighboring molecules bound to this patch, namely βC0 from
monomer 3 (blue ribbon) and βA0 from monomer 1' (green ribbon).
Strand βC0 buries Cys-16 and Ile-18, while strand βA0 buries
Ile-3 and Ala-5, into the center of the hydrophobic surface
patch. Residues Ser-20 of βC0 and Ser-7 of βA0 lie at the edge
of the interface and hydrogen-bond to monomer 1. Also shown in
yellow (at bottom horizon of surface) is the P3′ residue of a
modeled substrate polypeptide (see Figure 4), included here as a
directional reference to the active site.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Cell
(1996,
87,
331-342)
copyright 1996.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
B.Lee,
K.B.Kim,
S.Oh,
J.S.Choi,
J.S.Park,
D.H.Min,
and
D.E.Kim
(2010).
Suppression of hepatitis C virus genome replication in cells with RNA-cleaving DNA enzymes and short-hairpin RNA.
|
| |
Oligonucleotides, 20,
285-296.
|
 |
|
|
|
|
 |
N.Bostan,
and
T.Mahmood
(2010).
An overview about hepatitis C: a devastating virus.
|
| |
Crit Rev Microbiol, 36,
91.
|
 |
|
|
|
|
 |
Z.Zhu,
A.T.Wilson,
B.A.Luxon,
K.E.Brown,
M.M.Mathahs,
S.Bandyopadhyay,
A.P.McCaffrey,
and
W.N.Schmidt
(2010).
Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: Mechanism for the antiviral effects of heme oxygenase?
|
| |
Hepatology, 52,
1897-1905.
|
 |
|
|
|
|
 |
A.J.Thompson,
and
J.G.McHutchison
(2009).
Review article: investigational agents for chronic hepatitis C.
|
| |
Aliment Pharmacol Ther, 29,
689-705.
|
 |
|
|
|
|
 |
H.Tang,
and
H.Grisé
(2009).
Cellular and molecular biology of HCV infection and hepatitis.
|
| |
Clin Sci (Lond), 117,
49-65.
|
 |
|
|
|
|
 |
T.Phan,
R.K.Beran,
C.Peters,
I.C.Lorenz,
and
B.D.Lindenbach
(2009).
Hepatitis C virus NS2 protein contributes to virus particle assembly via opposing epistatic interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes.
|
| |
J Virol, 83,
8379-8395.
|
 |
|
|
|
|
 |
V.Meier,
and
G.Ramadori
(2009).
Hepatitis C virus virology and new treatment targets.
|
| |
Expert Rev Anti Infect Ther, 7,
329-350.
|
 |
|
|
|
|
 |
V.Schregel,
S.Jacobi,
F.Penin,
and
N.Tautz
(2009).
Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3.
|
| |
Proc Natl Acad Sci U S A, 106,
5342-5347.
|
 |
|
|
|
|
 |
V.Brass,
J.M.Berke,
R.Montserret,
H.E.Blum,
F.Penin,
and
D.Moradpour
(2008).
Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex.
|
| |
Proc Natl Acad Sci U S A, 105,
14545-14550.
|
 |
|
|
|
|
 |
C.L.Johnson,
D.M.Owen,
and
M.Gale
(2007).
Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense.
|
| |
J Biol Chem, 282,
10792-10803.
|
 |
|
|
|
|
 |
C.Oliva,
A.Rodríguez,
M.González,
and
W.Yang
(2007).
A quantum mechanics/molecular mechanics study of the reaction mechanism of the hepatitis C virus NS3 protease with the NS5A/5B substrate.
|
| |
Proteins, 66,
444-455.
|
 |
|
|
|
|
 |
J.M.Pawlotsky,
S.Chevaliez,
and
J.G.McHutchison
(2007).
The hepatitis C virus life cycle as a target for new antiviral therapies.
|
| |
Gastroenterology, 132,
1979-1998.
|
 |
|
|
|
|
 |
K.L.Maxwell,
and
L.Frappier
(2007).
Viral proteomics.
|
| |
Microbiol Mol Biol Rev, 71,
398-411.
|
 |
|
|
|
|
 |
M.S.Sulkowski
(2007).
Specific targeted antiviral therapy for hepatitis C.
|
| |
Curr Gastroenterol Rep, 9,
5.
|
 |
|
|
|
|
 |
R.De Francesco,
and
A.Carfí
(2007).
Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus.
|
| |
Adv Drug Deliv Rev, 59,
1242-1262.
|
 |
|
|
|
|
 |
S.Melino,
and
M.Paci
(2007).
Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.
|
| |
FEBS J, 274,
2986-3002.
|
 |
|
|
|
|
 |
T.L.Tellinghuisen,
M.J.Evans,
T.von Hahn,
S.You,
and
C.M.Rice
(2007).
Studying hepatitis C virus: making the best of a bad virus.
|
| |
J Virol, 81,
8853-8867.
|
 |
|
|
|
|
 |
T.Suzuki,
K.Ishii,
H.Aizaki,
and
T.Wakita
(2007).
Hepatitis C viral life cycle.
|
| |
Adv Drug Deliv Rev, 59,
1200-1212.
|
 |
|
|
|
|
 |
B.A.Malcolm,
R.Liu,
F.Lahser,
S.Agrawal,
B.Belanger,
N.Butkiewicz,
R.Chase,
F.Gheyas,
A.Hart,
D.Hesk,
P.Ingravallo,
C.Jiang,
R.Kong,
J.Lu,
J.Pichardo,
A.Prongay,
A.Skelton,
X.Tong,
S.Venkatraman,
E.Xia,
V.Girijavallabhan,
and
F.G.Njoroge
(2006).
SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.
|
| |
Antimicrob Agents Chemother, 50,
1013-1020.
|
 |
|
|
|
|
 |
I.C.Lorenz,
J.Marcotrigiano,
T.G.Dentzer,
and
C.M.Rice
(2006).
Structure of the catalytic domain of the hepatitis C virus NS2-3 protease.
|
| |
Nature, 442,
831-835.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Moriyama,
H.Matsumura,
A.Fukushima,
K.Ohkido,
Y.Arakawa,
K.Nirei,
H.Yamagami,
M.Kaneko,
N.Tanaka,
and
Y.Arakawa
(2006).
Clinical significance of evaluation of serum zinc concentrations in C-viral chronic liver disease.
|
| |
Dig Dis Sci, 51,
1967-1977.
|
 |
|
|
|
|
 |
N.Appel,
T.Schaller,
F.Penin,
and
R.Bartenschlager
(2006).
From structure to function: new insights into hepatitis C virus RNA replication.
|
| |
J Biol Chem, 281,
9833-9836.
|
 |
|
|
|
|
 |
P.Erbel,
N.Schiering,
A.D'Arcy,
M.Renatus,
M.Kroemer,
S.P.Lim,
Z.Yin,
T.H.Keller,
S.G.Vasudevan,
and
U.Hommel
(2006).
Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.
|
| |
Nat Struct Mol Biol, 13,
372-373.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.Zhang,
Z.Cai,
Y.C.Kim,
R.Kumar,
F.Yuan,
P.Y.Shi,
C.Kao,
and
G.Luo
(2005).
Stimulation of hepatitis C virus (HCV) nonstructural protein 3 (NS3) helicase activity by the NS3 protease domain and by HCV RNA-dependent RNA polymerase.
|
| |
J Virol, 79,
8687-8697.
|
 |
|
|
|
|
 |
H.Sakamoto,
K.Okamoto,
M.Aoki,
H.Kato,
A.Katsume,
A.Ohta,
T.Tsukuda,
N.Shimma,
Y.Aoki,
M.Arisawa,
M.Kohara,
and
M.Sudoh
(2005).
Host sphingolipid biosynthesis as a target for hepatitis C virus therapy.
|
| |
Nat Chem Biol, 1,
333-337.
|
 |
|
|
|
|
 |
J.C.Ferreon,
A.C.Ferreon,
K.Li,
and
S.M.Lemon
(2005).
Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease.
|
| |
J Biol Chem, 280,
20483-20492.
|
 |
|
|
|
|
 |
K.Watashi,
and
K.Shimotohno
(2005).
[Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents]
|
| |
Uirusu, 55,
105-110.
|
 |
|
|
|
|
 |
R.De Francesco,
and
G.Migliaccio
(2005).
Challenges and successes in developing new therapies for hepatitis C.
|
| |
Nature, 436,
953-960.
|
 |
|
|
|
|
 |
U.C.Chaturvedi,
and
R.Shrivastava
(2005).
Interaction of viral proteins with metal ions: role in maintaining the structure and functions of viruses.
|
| |
FEMS Immunol Med Microbiol, 43,
105-114.
|
 |
|
|
|
|
 |
X.D.Li,
L.Sun,
R.B.Seth,
G.Pineda,
and
Z.J.Chen
(2005).
Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity.
|
| |
Proc Natl Acad Sci U S A, 102,
17717-17722.
|
 |
|
|
|
|
 |
C.Lin,
K.Lin,
Y.P.Luong,
B.G.Rao,
Y.Y.Wei,
D.L.Brennan,
J.R.Fulghum,
H.M.Hsiao,
S.Ma,
J.P.Maxwell,
K.M.Cottrell,
R.B.Perni,
C.A.Gates,
and
A.D.Kwong
(2004).
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.
|
| |
J Biol Chem, 279,
17508-17514.
|
 |
|
|
|
|
 |
F.Penin,
J.Dubuisson,
F.A.Rey,
D.Moradpour,
and
J.M.Pawlotsky
(2004).
Structural biology of hepatitis C virus.
|
| |
Hepatology, 39,
5.
|
 |
|
|
|
|
 |
H.Hinrichsen,
Y.Benhamou,
H.Wedemeyer,
M.Reiser,
R.E.Sentjens,
J.L.Calleja,
X.Forns,
A.Erhardt,
J.Crönlein,
R.L.Chaves,
C.L.Yong,
G.Nehmiz,
and
G.G.Steinmann
(2004).
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.
|
| |
Gastroenterology, 127,
1347-1355.
|
 |
|
|
|
|
 |
J.M.Pawlotsky,
and
J.G.McHutchison
(2004).
Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003.
|
| |
Hepatology, 39,
554-567.
|
 |
|
|
|
|
 |
J.M.Pawlotsky
(2004).
Hepatitis C: it's a long way to new therapy, it's a long way to go...
|
| |
Gastroenterology, 127,
1629-1632.
|
 |
|
|
|
|
 |
M.Shokhen,
and
A.Albeck
(2004).
Identification of protons position in acid-base enzyme catalyzed reactions: the hepatitis C viral NS3 protease.
|
| |
Proteins, 55,
245-250.
|
 |
|
|
|
|
 |
P.Niyomrattanakit,
P.Winoyanuwattikun,
S.Chanprapaph,
C.Angsuthanasombat,
S.Panyim,
and
G.Katzenmeier
(2004).
Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation.
|
| |
J Virol, 78,
13708-13716.
|
 |
|
|
|
|
 |
T.Lackner,
A.Müller,
A.Pankraz,
P.Becher,
H.J.Thiel,
A.E.Gorbalenya,
and
N.Tautz
(2004).
Temporal modulation of an autoprotease is crucial for replication and pathogenicity of an RNA virus.
|
| |
J Virol, 78,
10765-10775.
|
 |
|
|
|
|
 |
V.Brass,
H.E.Blum,
and
D.Moradpour
(2004).
Recent developments in target identification against hepatitis C virus.
|
| |
Expert Opin Ther Targets, 8,
295-307.
|
 |
|
|
|
|
 |
W.Wang,
F.C.Lahser,
M.Yi,
J.Wright-Minogue,
E.Xia,
P.C.Weber,
S.M.Lemon,
and
B.A.Malcolm
(2004).
Conserved C-terminal threonine of hepatitis C virus NS3 regulates autoproteolysis and prevents product inhibition.
|
| |
J Virol, 78,
700-709.
|
 |
|
|
|
|
 |
Y.S.Tsantrizos
(2004).
The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
|
| |
Biopolymers, 76,
309-323.
|
 |
|
|
|
|
 |
A.Pause,
G.Kukolj,
M.Bailey,
M.Brault,
F.Dô,
T.Halmos,
L.Lagacé,
R.Maurice,
M.Marquis,
G.McKercher,
C.Pellerin,
L.Pilote,
D.Thibeault,
and
D.Lamarre
(2003).
An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA.
|
| |
J Biol Chem, 278,
20374-20380.
|
 |
|
|
|
|
 |
C.Trozzi,
L.Bartholomew,
A.Ceccacci,
G.Biasiol,
L.Pacini,
S.Altamura,
F.Narjes,
E.Muraglia,
G.Paonessa,
U.Koch,
R.De Francesco,
C.Steinkuhler,
and
G.Migliaccio
(2003).
In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.
|
| |
J Virol, 77,
3669-3679.
|
 |
|
|
|
|
 |
F.Narjes,
U.Koch,
and
C.Steinkühler
(2003).
Recent developments in the discovery of hepatitis C virus serine protease inhibitors--towards a new class of antiviral agents?
|
| |
Expert Opin Investig Drugs, 12,
153-163.
|
 |
|
|
|
|
 |
L.Vasiljeva,
A.Merits,
A.Golubtsov,
V.Sizemskaja,
L.Kääriäinen,
and
T.Ahola
(2003).
Regulation of the sequential processing of Semliki Forest virus replicase polyprotein.
|
| |
J Biol Chem, 278,
41636-41645.
|
 |
|
|
|
|
 |
M.P.Walker,
N.Yao,
and
Z.Hong
(2003).
Promising candidates for the treatment of chronic hepatitis C.
|
| |
Expert Opin Investig Drugs, 12,
1269-1280.
|
 |
|
|
|
|
 |
M.Wang,
K.K.Ng,
M.M.Cherney,
L.Chan,
C.G.Yannopoulos,
J.Bedard,
N.Morin,
N.Nguyen-Ba,
M.H.Alaoui-Ismaili,
R.C.Bethell,
and
M.N.James
(2003).
Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition.
|
| |
J Biol Chem, 278,
9489-9495.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Ogata,
R.H.Florese,
M.Nagano-Fujii,
R.Hidajat,
L.Deng,
Y.Ku,
S.Yoon,
T.Saito,
S.Kawata,
and
H.Hotta
(2003).
Identification of hepatitis C virus (HCV) subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the HCV NS3 protein.
|
| |
J Clin Microbiol, 41,
2835-2841.
|
 |
|
|
|
|
 |
A.Casbarra,
F.D.Piaz,
P.Ingallinella,
S.Orrù,
P.Pucci,
A.Pessi,
and
E.Bianchi
(2002).
The effect of prime-site occupancy on the hepatitis C virus NS3 protease structure.
|
| |
Protein Sci, 11,
2102-2112.
|
 |
|
|
|
|
 |
E.Bianchi,
and
A.Pessi
(2002).
Inhibiting viral proteases: challenges and opportunities.
|
| |
Biopolymers, 66,
101-114.
|
 |
|
|
|
|
 |
P.Ingallinella,
D.Fattori,
S.Altamura,
C.Steinkühler,
U.Koch,
D.Cicero,
R.Bazzo,
R.Cortese,
E.Bianchi,
and
A.Pessi
(2002).
Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus.
|
| |
Biochemistry, 41,
5483-5492.
|
 |
|
|
|
|
 |
P.S.Pang,
E.Jankowsky,
P.J.Planet,
and
A.M.Pyle
(2002).
The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding.
|
| |
EMBO J, 21,
1168-1176.
|
 |
|
|
|
|
 |
S.J.Archer,
D.M.Camac,
Z.J.Wu,
N.A.Farrow,
P.J.Domaille,
Z.R.Wasserman,
M.Bukhtiyarova,
C.Rizzo,
S.Jagannathan,
L.J.Mersinger,
and
C.A.Kettner
(2002).
Hepatitis C virus NS3 protease requires its NS4A cofactor peptide for optimal binding of a boronic acid inhibitor as shown by NMR.
|
| |
Chem Biol, 9,
79-92.
|
 |
|
|
|
|
 |
A.Pessi
(2001).
A personal account of the role of peptide research in drug discovery: the case of hepatitis C.
|
| |
J Pept Sci, 7,
2.
|
 |
|
|
|
|
 |
B.W.Dymock
(2001).
Emerging therapies for hepatitis C virus infection.
|
| |
Expert Opin Emerg Drugs, 6,
13-42.
|
 |
|
|
|
|
 |
K.Hara,
M.Shiota,
H.Kido,
Y.Ohtsu,
T.Kashiwagi,
J.Iwahashi,
N.Hamada,
K.Mizoue,
N.Tsumura,
H.Kato,
and
T.Toyoda
(2001).
Influenza virus RNA polymerase PA subunit is a novel serine protease with Ser624 at the active site.
|
| |
Genes Cells, 6,
87-97.
|
 |
|
|
|
|
 |
P.Borowski,
A.Niebuhr,
O.Mueller,
M.Bretner,
K.Felczak,
T.Kulikowski,
and
H.Schmitz
(2001).
Purification and characterization of West Nile virus nucleoside triphosphatase (NTPase)/helicase: evidence for dissociation of the NTPase and helicase activities of the enzyme.
|
| |
J Virol, 75,
3220-3229.
|
 |
|
|
|
|
 |
R.Banerjee,
and
A.Dasgupta
(2001).
Specific interaction of hepatitis C virus protease/helicase NS3 with the 3'-terminal sequences of viral positive- and negative-strand RNA.
|
| |
J Virol, 75,
1708-1721.
|
 |
|
|
|
|
 |
T.Heintges,
J.Encke,
J.zu Putlitz,
and
J.R.Wands
(2001).
Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor.
|
| |
J Med Virol, 65,
671-680.
|
 |
|
|
|
|
 |
W.T.Sing,
C.L.Lee,
S.L.Yeo,
S.P.Lim,
and
M.M.Sim
(2001).
Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor.
|
| |
Bioorg Med Chem Lett, 11,
91-94.
|
 |
|
|
|
|
 |
Y.L.Khu,
E.Koh,
S.P.Lim,
Y.H.Tan,
S.Brenner,
S.G.Lim,
W.J.Hong,
and
P.Y.Goh
(2001).
Mutations that affect dimer formation and helicase activity of the hepatitis C virus helicase.
|
| |
J Virol, 75,
205-214.
|
 |
|
|
|
|
 |
A.Kanjanahaluethai,
and
S.C.Baker
(2000).
Identification of mouse hepatitis virus papain-like proteinase 2 activity.
|
| |
J Virol, 74,
7911-7921.
|
 |
|
|
|
|
 |
B.Wölk,
D.Sansonno,
H.G.Kräusslich,
F.Dammacco,
C.M.Rice,
H.E.Blum,
and
D.Moradpour
(2000).
Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines.
|
| |
J Virol, 74,
2293-2304.
|
 |
|
|
|
|
 |
D.Fattori,
A.Urbani,
M.Brunetti,
R.Ingenito,
A.Pessi,
K.Prendergast,
F.Narjes,
V.G.Matassa,
R.De Francesco,
and
C.Steinkühler
(2000).
Probing the active site of the hepatitis C virus serine protease by fluorescence resonance energy transfer.
|
| |
J Biol Chem, 275,
15106-15113.
|
 |
|
|
|
|
 |
F.López-Jiménez,
M.Brito,
Y.W.Aude,
P.Scheinberg,
M.Kaplan,
D.A.Dixon,
N.Schneiderman,
J.F.Trejo,
L.H.López-Salazar,
E.J.Ramírez-Barba,
R.Kalil,
C.Ortiz,
J.Goyos,
A.Buenaño,
S.Kottiech,
and
G.A.Lamas
(2000).
Update in internal medicine.
|
| |
Arch Med Res, 31,
329-352.
|
 |
|
|
|
|
 |
G.Barbato,
D.O.Cicero,
F.Cordier,
F.Narjes,
B.Gerlach,
S.Sambucini,
S.Grzesiek,
V.G.Matassa,
R.De Francesco,
and
R.Bazzo
(2000).
Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain.
|
| |
EMBO J, 19,
1195-1206.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Encke,
and
J.R.Wands
(2000).
Ethanol inhibition: the humoral and cellular immune response to hepatitis C virus NS5 protein after genetic immunization.
|
| |
Alcohol Clin Exp Res, 24,
1063-1069.
|
 |
|
|
|
|
 |
K.Fukuda,
D.Vishnuvardhan,
S.Sekiya,
J.Hwang,
N.Kakiuchi,
K.Taira,
K.Shimotohno,
P.K.Kumar,
and
S.Nishikawa
(2000).
Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease.
|
| |
Eur J Biochem, 267,
3685-3694.
|
 |
|
|
|
|
 |
L.Pacini,
A.Vitelli,
G.Filocamo,
L.Bartholomew,
M.Brunetti,
A.Tramontano,
C.Steinkühler,
and
G.Migliaccio
(2000).
In vivo selection of protease cleavage sites by using chimeric Sindbis virus libraries.
|
| |
J Virol, 74,
10563-10570.
|
 |
|
|
|
|
 |
N.Butkiewicz,
N.Yao,
W.Zhong,
J.Wright-Minogue,
P.Ingravallo,
R.Zhang,
J.Durkin,
D.N.Standring,
B.M.Baroudy,
D.V.Sangar,
S.M.Lemon,
J.Y.Lau,
and
Z.Hong
(2000).
Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3.
|
| |
J Virol, 74,
4291-4301.
|
 |
|
|
|
|
 |
N.Kato
(2000).
Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation.
|
| |
Microb Comp Genomics, 5,
129-151.
|
 |
|
|
|
|
 |
S.Di Marco,
M.Rizzi,
C.Volpari,
M.A.Walsh,
F.Narjes,
S.Colarusso,
R.De Francesco,
V.G.Matassa,
and
M.Sollazzo
(2000).
Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes.
|
| |
J Biol Chem, 275,
7152-7157.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.Ueno,
S.Misawa,
Y.Ohba,
M.Matsumoto,
M.Mizunuma,
N.Kasai,
K.Tsumoto,
I.Kumagai,
and
H.Hayashi
(2000).
Isolation and characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 protease.
|
| |
J Virol, 74,
6300-6308.
|
 |
|
|
|
|
 |
E.Ferrari,
J.Wright-Minogue,
J.W.Fang,
B.M.Baroudy,
J.Y.Lau,
and
Z.Hong
(1999).
Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli.
|
| |
J Virol, 73,
1649-1654.
|
 |
|
|
|
|
 |
G.Filocamo,
L.Pacini,
C.Nardi,
L.Bartholomew,
M.Scaturro,
P.Delmastro,
A.Tramontano,
R.De Francesco,
and
G.Migliaccio
(1999).
Selection of functional variants of the NS3-NS4A protease of hepatitis C virus by using chimeric sindbis viruses.
|
| |
J Virol, 73,
561-575.
|
 |
|
|
|
|
 |
H.Ago,
T.Adachi,
A.Yoshida,
M.Yamamoto,
N.Habuka,
K.Yatsunami,
and
M.Miyano
(1999).
Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus.
|
| |
Structure, 7,
1417-1426.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.M.Murthy,
S.Clum,
and
R.Padmanabhan
(1999).
Dengue virus NS3 serine protease. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects.
|
| |
J Biol Chem, 274,
5573-5580.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.D.Tyndall,
and
D.P.Fairlie
(1999).
Conformational homogeneity in molecular recognition by proteolytic enzymes.
|
| |
J Mol Recognit, 12,
363-370.
|
 |
|
|
|
|
 |
J.F.Petersen,
M.M.Cherney,
H.D.Liebig,
T.Skern,
E.Kuechler,
and
M.N.James
(1999).
The structure of the 2A proteinase from a common cold virus: a proteinase responsible for the shut-off of host-cell protein synthesis.
|
| |
EMBO J, 18,
5463-5475.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Herold,
S.G.Siddell,
and
A.E.Gorbalenya
(1999).
A human RNA viral cysteine proteinase that depends upon a unique Zn2+-binding finger connecting the two domains of a papain-like fold .
|
| |
J Biol Chem, 274,
14918-14925.
|
 |
|
|
|
|
 |
N.Yao,
P.Reichert,
S.S.Taremi,
W.W.Prosise,
and
P.C.Weber
(1999).
Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase.
|
| |
Structure, 7,
1353-1363.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
P.L.Darke,
A.R.Jacobs,
L.Waxman,
and
L.C.Kuo
(1999).
Inhibition of hepatitis C virus NS2/3 processing by NS4A peptides. Implications for control of viral processing.
|
| |
J Biol Chem, 274,
34511-34514.
|
 |
|
|
|
|
 |
S.Orrù,
F.Dal Piaz,
A.Casbarra,
G.Biasiol,
R.De Francesco,
C.Steinkühler,
and
P.Pucci
(1999).
Conformational changes in the NS3 protease from hepatitis C virus strain Bk monitored by limited proteolysis and mass spectrometry.
|
| |
Protein Sci, 8,
1445-1454.
|
 |
|
|
|
|
 |
S.R.LaPlante,
D.R.Cameron,
N.Aubry,
S.Lefebvre,
G.Kukolj,
R.Maurice,
D.Thibeault,
D.Lamarre,
and
M.Llinàs-Brunet
(1999).
Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain.
|
| |
J Biol Chem, 274,
18618-18624.
|
 |
|
|
|
|
 |
A.Guarné,
J.Tormo,
R.Kirchweger,
D.Pfistermueller,
I.Fita,
and
T.Skern
(1998).
Structure of the foot-and-mouth disease virus leader protease: a papain-like fold adapted for self-processing and eIF4G recognition.
|
| |
EMBO J, 17,
7469-7479.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.K.Patick,
and
K.E.Potts
(1998).
Protease inhibitors as antiviral agents.
|
| |
Clin Microbiol Rev, 11,
614-627.
|
 |
|
|
|
|
 |
A.S.Belyaev,
S.Chong,
A.Novikov,
A.Kongpachith,
F.R.Masiarz,
M.Lim,
and
J.P.Kim
(1998).
Hepatitis G virus encodes protease activities which can effect processing of the virus putative nonstructural proteins.
|
| |
J Virol, 72,
868-872.
|
 |
|
|
|
|
 |
A.Urbani,
R.Bazzo,
M.C.Nardi,
D.O.Cicero,
R.De Francesco,
C.Steinkühler,
and
G.Barbato
(1998).
The metal binding site of the hepatitis C virus NS3 protease. A spectroscopic investigation.
|
| |
J Biol Chem, 273,
18760-18769.
|
 |
|
|
|
|
 |
B.Duffy,
C.Schwietert,
A.France,
N.Mann,
K.Culbertson,
B.Harmon,
and
J.P.McCue
(1998).
Transition metals as protease inhibitors.
|
| |
Biol Trace Elem Res, 64,
197-213.
|
 |
|
|
|
|
 |
D.Moradpour,
P.Kary,
C.M.Rice,
and
H.E.Blum
(1998).
Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins.
|
| |
Hepatology, 28,
192-201.
|
 |
|
|
|
|
 |
L.W.Kang,
H.S.Cho,
S.S.Cha,
K.M.Chung,
S.H.Back,
S.K.Jang,
and
B.H.Oh
(1998).
Crystallization and preliminary X-ray crystallographic analysis of the helicase domain of hepatitis C virus NS3 protein.
|
| |
Acta Crystallogr D Biol Crystallogr, 54,
121-123.
|
 |
|
|
|
|
 |
M.Llinàs-Brunet,
M.Bailey,
R.Déziel,
G.Fazal,
V.Gorys,
S.Goulet,
T.Halmos,
R.Maurice,
M.Poirier,
M.A.Poupart,
J.Rancourt,
D.Thibeault,
D.Wernic,
and
D.Lamarre
(1998).
Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.
|
| |
Bioorg Med Chem Lett, 8,
2719-2724.
|
 |
|
|
|
|
 |
P.Gallinari,
D.Brennan,
C.Nardi,
M.Brunetti,
L.Tomei,
C.Steinkühler,
and
R.De Francesco
(1998).
Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus.
|
| |
J Virol, 72,
6758-6769.
|
 |
|
|
|
|
 |
R.P.Valle,
and
B.Falgout
(1998).
Mutagenesis of the NS3 protease of dengue virus type 2.
|
| |
J Virol, 72,
624-632.
|
 |
|
|
|
|
 |
S.S.Taremi,
B.Beyer,
M.Maher,
N.Yao,
W.Prosise,
P.C.Weber,
and
B.A.Malcolm
(1998).
Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease.
|
| |
Protein Sci, 7,
2143-2149.
|
 |
|
|
|
|
 |
Z.Wu,
N.Yao,
H.V.Le,
and
P.C.Weber
(1998).
Mechanism of autoproteolysis at the NS2-NS3 junction of the hepatitis C virus polyprotein.
|
| |
Trends Biochem Sci, 23,
92-94.
|
 |
|
|
|
|
 |
C.Lin,
J.W.Wu,
K.Hsiao,
and
M.S.Su
(1997).
The hepatitis C virus NS4A protein: interactions with the NS4B and NS5A proteins.
|
| |
J Virol, 71,
6465-6471.
|
 |
|
|
|
|
 |
E.Scarselli,
A.Urbani,
A.Sbardellati,
L.Tomei,
R.De Francesco,
and
C.Traboni
(1997).
GB virus B and hepatitis C virus NS3 serine proteases share substrate specificity.
|
| |
J Virol, 71,
4985-4989.
|
 |
|
|
|
|
 |
G.M.Heilek,
and
M.G.Peterson
(1997).
A point mutation abolishes the helicase but not the nucleoside triphosphatase activity of hepatitis C virus NS3 protein.
|
| |
J Virol, 71,
6264-6266.
|
 |
|
|
|
|
 |
J.Xu,
E.Mendez,
P.R.Caron,
C.Lin,
M.A.Murcko,
M.S.Collett,
and
C.M.Rice
(1997).
Bovine viral diarrhea virus NS3 serine proteinase: polyprotein cleavage sites, cofactor requirements, and molecular model of an enzyme essential for pestivirus replication.
|
| |
J Virol, 71,
5312-5322.
|
 |
|
|
|
|
 |
L.Pieroni,
E.Santolini,
C.Fipaldini,
L.Pacini,
G.Migliaccio,
and
N.La Monica
(1997).
In vitro study of the NS2-3 protease of hepatitis C virus.
|
| |
J Virol, 71,
6373-6380.
|
 |
|
|
|
|
 |
M.Stempniak,
Z.Hostomska,
B.R.Nodes,
and
Z.Hostomsky
(1997).
The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme.
|
| |
J Virol, 71,
2881-2886.
|
 |
|
|
|
|
 |
N.Dimasi,
F.Martin,
C.Volpari,
M.Brunetti,
G.Biasiol,
S.Altamura,
R.Cortese,
R.De Francesco,
C.Steinkühler,
and
M.Sollazzo
(1997).
Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.
|
| |
J Virol, 71,
7461-7469.
|
 |
|
|
|
|
 |
N.Tautz,
K.Elbers,
D.Stoll,
G.Meyers,
and
H.J.Thiel
(1997).
Serine protease of pestiviruses: determination of cleavage sites.
|
| |
J Virol, 71,
5415-5422.
|
 |
|
|
|
|
 |
N.Yao,
T.Hesson,
M.Cable,
Z.Hong,
A.D.Kwong,
H.V.Le,
and
P.C.Weber
(1997).
Structure of the hepatitis C virus RNA helicase domain.
|
| |
Nat Struct Biol, 4,
463-467.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.Zhang,
J.Durkin,
W.T.Windsor,
C.McNemar,
L.Ramanathan,
and
H.V.Le
(1997).
Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides.
|
| |
J Virol, 71,
6208-6213.
|
 |
|
|
|
|
 |
S.Muramatsu,
S.Ishido,
T.Fujita,
M.Itoh,
and
H.Hotta
(1997).
Nuclear localization of the NS3 protein of hepatitis C virus and factors affecting the localization.
|
| |
J Virol, 71,
4954-4961.
|
 |
|
|
|
|
 |
S.Spada,
C.Krebber,
and
A.Plückthun
(1997).
Selectively infective phages (SIP).
|
| |
Biol Chem, 378,
445-456.
|
 |
|
|
|
|
 |
V.Lohmann,
F.Körner,
U.Herian,
and
R.Bartenschlager
(1997).
Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity.
|
| |
J Virol, 71,
8416-8428.
|
 |
|
|
|
|
 |
W.F.Mangel,
D.L.Toledo,
J.Ding,
R.M.Sweet,
and
W.J.McGrath
(1997).
Temporal and spatial control of the adenovirus proteinase by both a peptide and the viral DNA.
|
| |
Trends Biochem Sci, 22,
393-398.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
|